###begin article-title 0
###xml 78 86 78 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In Vitro</italic>
###xml 57 60 <span type="species:ncbi:10116">Rat</span>
Over Expression of Plk1 Does Not Induce Cell Division in Rat Cardiac Myocytes In Vitro
###end article-title 0
###begin p 1
Conceived and designed the experiments: KB GB. Performed the experiments: CHC. Analyzed the data: CHC. Contributed reagents/materials/analysis tools: KB FLM. Wrote the paper: CHC.
###end p 1
###begin p 2
Current address: Innovex Medical Communications, Bracknell, United Kingdom
###end p 2
###begin title 3
Background
###end title 3
###begin p 4
Mammalian cardiac myocytes withdraw from the cell cycle during post-natal development, resulting in a non-proliferating, fully differentiated adult phenotype that is unable to repair damage to the myocardium, such as occurs following a myocardial infarction. We and others previously have shown that forced expression of certain cell cycle molecules in adult cardiac myocytes can promote cell cycle progression and division in these cells. The mitotic serine/threonine kinase, Polo-like kinase-1 (Plk1), is known to phosphorylate and activate a number of mitotic targets, including Cdc2/Cyclin B1, and to promote cell division.
###end p 4
###begin title 5
Principal Findings
###end title 5
###begin p 6
###xml 84 87 <span type="species:ncbi:10116">rat</span>
###xml 294 297 <span type="species:ncbi:10116">rat</span>
###xml 454 457 <span type="species:ncbi:10116">rat</span>
The mammalian Plk family are all differentially regulated during the development of rat cardiac myocytes, with Plk1 showing the most dramatic decrease in both mRNA, protein and activity in the adult. We determined the potential of Plk1 to induce cell cycle progression and division in cultured rat cardiac myocytes. A persistent and progressive loss of Plk1 expression was observed during myocyte development that correlated with the withdrawal of adult rat cardiac myocytes from the cell cycle. Interestingly, when Plk1 was over-expressed in cardiac myocytes by adenovirus infection, it was not able to promote cell cycle progression, as determined by cell number and percent binucleation.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
We conclude that, in contrast to Cdc2/Cyclin B1 over-expression, the forced expression of Plk1 in adult cardiac myocytes is not sufficient to induce cell division and myocardial repair.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 75 78 75 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Soonpaa1">[1]</xref>
###xml 79 82 79 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Huttenbach1">[4]</xref>
###xml 656 659 656 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Sutton1">[5]</xref>
###xml 660 663 660 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Opie1">[7]</xref>
Mammalian cardiac myocytes lose the ability to divide shortly after birth, [1]-[4], differentiating into cell cycle arrested binucleated cells. Subsequent growth of the myocardium is achieved through an increase in myocyte cell size, known as hypertrophy. Following myocardial injury, cardiac myocytes are lost from the damaged area and replaced by scar tissue. Any loss in cardiac function is compensated by a physiological hypertrophic response and cardiac remodeling. Although this process initially helps to maintain cardiac output, the remodeling process continues and eventually leads to the development of pathological hypertrophy and heart failure [5]-[7].
###end p 10
###begin p 11
###xml 173 176 173 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Brooks1">[8]</xref>
###xml 177 181 177 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Li1">[15]</xref>
###xml 584 585 584 585 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 587 588 587 588 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 651 655 651 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Li1">[15]</xref>
The change in growth potential of cardiac myocytes during cardiac development and hypertrophy is reflected in the expressions and activities of certain cell cycle molecules.[8]-[15] Thus, positive regulators of the cell cycle machinery, such as the Cdk/cyclin complexes and the pro-proliferative E2F transcription factors (E2F1-3) are down regulated, whilst negative regulators, including retinoblastoma protein (pRb) and the cyclin-dependent kinase inhibitors (CDKIs), p21 and p27, are upregulated. As a consequence, the majority of adult mammalian cardiac myocytes are arrested in G0/G1, with the remaining cells being present at the G2/M transition[15].
###end p 11
###begin p 12
###xml 235 239 235 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Rubart1">[16]</xref>
###xml 241 245 241 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Bicknell1">[17]</xref>
###xml 311 315 311 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Vara1">[12]</xref>
###xml 317 321 317 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Movassagh1">[13]</xref>
###xml 323 327 323 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Bicknell2">[18]</xref>
###xml 604 612 604 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 613 617 613 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Bicknell2">[18]</xref>
###xml 618 622 618 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Pasumarthi1">[25]</xref>
###xml 660 668 660 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 668 672 668 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Vara1">[12]</xref>
###xml 707 711 707 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Poolman2">[14]</xref>
###xml 713 717 713 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Chaudhry1">[24]</xref>
###xml 747 751 747 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Pasumarthi1">[25]</xref>
###xml 753 757 753 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Hassink1">[26]</xref>
###xml 757 764 757 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 219 226 <span type="species:ncbi:9606">patient</span>
###xml 977 984 <span type="species:ncbi:9606">patient</span>
Current strategies aimed at encouraging repair of the heart focus on the use of stem cells or gene therapy to induce cell division and differentiation at the site of damage to reduce the size of the infarct and improve patient outcome.[16], [17] In support of the gene therapy approach, work from our laboratory[12], [13], [18] and others (see below) have shown that manipulation of the cardiac myocyte cell cycle machinery could be a suitable therapeutic approach for promoting myocardial repair. Alterations in the expressions of certain cell cycle molecules can increase cardiac myocyte proliferation in vitro,[18]-[25] inhibit the induction of hypertrophy in vitro[12] or increase cardiac myocyte number[14], [24] and promote myocardial repair[25], [26]in vivo. These studies have highlighted a number of potential targets for the reinitiation of cardiac myocyte cell division, with the aim of increasing the number of cardiac myocytes and reducing infarct size to improve patient outcome.
###end p 12
###begin p 13
###xml 276 280 276 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Nigg1">[27]</xref>
###xml 282 286 282 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Barr1">[28]</xref>
###xml 364 368 364 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Lee1">[29]</xref>
###xml 369 373 369 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Elia1">[32]</xref>
###xml 479 493 479 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xenopus laevis</italic>
###xml 499 503 499 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Kumagai1">[33]</xref>
###xml 503 528 503 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Schizosaccharomyces pombe</italic>
###xml 539 563 539 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Saccharomyces cerevisiae</italic>
###xml 569 573 569 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Kitada1">[34]</xref>
###xml 574 578 574 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Lee2">[36]</xref>
###xml 479 493 <span type="species:ncbi:8355">Xenopus laevis</span>
###xml 503 528 <span type="species:ncbi:4896">Schizosaccharomyces pombe</span>
###xml 539 563 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
The Polo-like kinases (Plks) are a family of serine/threonine kinases that exhibit sequence identity in both their N-terminal catalytic domain and their C-terminal region, which is termed the polo-box domain (PBD). This C-terminal region contains phosphopeptide binding motifs[27], [28], called 'polo-boxes', that are essential for Plk localization and regulation.[29]-[32] This family of kinases includes the mammalian Plks: Plk1, Plk2 (Snk), Plk3 (Fnk/Prk) and Plk4 (Sak-a/b); Xenopus laevis Plx1,[33]Schizosaccharomyces pombe plo1+ and Saccharomyces cerevisiae CDC5 [34]-[36].
###end p 13
###begin p 14
###xml 131 135 131 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-ToyoshimaMorimoto1">[37]</xref>
###xml 157 161 157 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Feng1">[38]</xref>
###xml 162 166 162 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-ToyoshimaMorimoto2">[42]</xref>
###xml 188 192 188 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-ToyoshimaMorimoto2">[42]</xref>
###xml 213 217 213 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Watanabe1">[43]</xref>
###xml 219 223 219 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-vanVugt1">[44]</xref>
###xml 233 237 233 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Nakajima1">[45]</xref>
###xml 383 387 383 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Feng2">[46]</xref>
###xml 389 393 389 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Golan1">[47]</xref>
###xml 480 484 480 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Petronczki1">[48]</xref>
###xml 486 490 486 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Lowery1">[49]</xref>
###xml 573 577 573 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Petronczki1">[48]</xref>
###xml 579 583 579 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Lenart1">[50]</xref>
###xml 585 589 585 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Steegmaier1">[51]</xref>
###xml 761 765 761 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Warnke1">[52]</xref>
###xml 791 795 791 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Dai1">[53]</xref>
###xml 832 836 832 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Xie1">[54]</xref>
###xml 939 943 939 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Lowery2">[55]</xref>
###xml 1165 1169 1165 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Ko1">[56]</xref>
###xml 1170 1174 1170 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Habedanck1">[59]</xref>
###xml 469 474 <span type="species:ncbi:9606">human</span>
Plk1 is important for mitotic progression (karyokinesis and cytokinesis); it is involved in the nuclear translocation of cyclin B1,[37] microtubule dynamics,[38]-[42] activation of Cdc25C,[42] inactivation of Wee1[43], [44] and Myt1,[45] separation of chromosomes at anaphase and destruction of mitotic proteins through activation of the anaphase promoting complex/cyclosome (APC/C).[46], [47] Recently, it has been demonstrated that Plk1 contributes to cytokinesis in human cells[48], [49] and that inhibition of Plk1 activity with the highly selective inhibitor, BI 2536,[48], [50], [51] results in cytokinesis failure and the generation of binucleated cells. Plk2-4 display varying roles in cell cycle progression: Plk2 plays a role in centriole duplication;[52] Plk3 is a non-cycling Plk[53] involved in G2 checkpoint signaling.[54] Plk4 differs from Plk1-3 as it contains a variation of the Plk kinase motif and has a single polo-box.[55] Plk4 has been shown to localize to centrioles and, like Plk2, is thought to be important for centriole duplication. Loss or over expression of Plk4 results in defects in the centriole cycle and aberrant spindle formation [56]-[59].
###end p 14
###begin p 15
###xml 100 104 100 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Georgescu1">[60]</xref>
###xml 401 405 401 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Georgescu1">[60]</xref>
###xml 68 71 <span type="species:ncbi:10116">rat</span>
###xml 214 217 <span type="species:ncbi:10116">rat</span>
###xml 990 993 <span type="species:ncbi:10116">rat</span>
###xml 1036 1039 <span type="species:ncbi:10116">rat</span>
Previously, Plk1 mRNA and protein have been shown to decline during rat cardiac myocyte development.[60] We have extended these studies and characterized the expression of the whole family of mammalian Plks during rat cardiac myocyte development. We confirmed that the expression and activity of Plk1 in cardiac myocytes declines during development in accordance with observations previously reported.[60] Plk2, Plk3 and Plk4 also showed small, but significant, changes at the mRNA and protein levels during development. In addition, we have tested the hypothesis that over expression of Plk1 would reinitiate the cell cycle in G2/M-arrested cells and increase the number of cardiac myocytes. Adenovirus constructs were generated to express wild-type Plk1 or a constitutively active Plk1 with the phospho-mimicking T210D mutation. Despite being able to increase HeLa cell proliferation, we found that over expression of Plk1 was unable to induce cell cycle progression in isolated neonatal rat cardiac myocytes at 48 hours, or in adult rat cardiac myocytes at 24 hours. We found that this most likely due to the inability of Plk1 to increase the activity of Cdc2/cyclin B1. Based on these findings, we sought to further characterize the G2/M arrest originally observed in adult cardiac myocytes with the aim of determining a more precise description of the G2/M arrest. Using an immunohistochemical approach, we found no evidence of G2/M marker expression in the adult myocardium and conclude that this may be indicative of an earlier arrest.
###end p 15
###begin title 16
Materials and Methods
###end title 16
###begin title 17
Ethics Statement
###end title 17
###begin p 18
###xml 58 69 <span type="species:ncbi:10116">Wistar rats</span>
Ventricular cardiac myocytes were isolated from wild type Wistar rats which were housed and maintained in a colony in accordance with the Local Ethical Review Panel of the University of Reading and U.K. Home Office guidelines. All experimental procedures using animals were performed in accordance with the U.K. Animals (Scientific Procedures) Act, 1986.
###end p 18
###begin title 19
Materials
###end title 19
###begin p 20
###xml 1231 1242 <span type="species:ncbi:3704">Horseradish</span>
###xml 1368 1373 <span type="species:ncbi:10090">mouse</span>
Dual-labeled quantitative PCR probes and oligonucleotides were synthesized by Sigma-Genosys (Pampisford, U.K.). ABgene Absolute QPCR Rox Mix (ABgene; Epsom, UK) was used according to the manufacturer's instructions. Samples were normalized to either the ribosomal subunit, 18S, using the 18S QPCR kit (Applied Biosystems, Warrington, UK) or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) QPCR kit (Applied Biosystems, Warrington, UK). Samples were amplified on an Applied Biosystems 5700 GeneAmp QPCR machine. The High-Fidelity PCR system was supplied by Roche Diagnostics (Lewes, U.K.). Anti-(cyclin B1) (GNS1) and anti-(CDC2 p34), antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). Anti-Plk1 monoclonal antibody cocktail was purchased from Zymed (Invitrogen, Paisley, U.K.). Anti-Plk2 and Plk4 antibodies were purchased from Bethyl Laboratories (Montgomery, TX, U.S.A.), and an anti-Fnk/Plk3 antibody was purchased from BD Biosciences. The anti-tropomyosin (sarcomeric) antibody (clone CH1) was obtained from Sigma (Poole, U.K.). Anti-Histone H3 Ser10 antibody was purchased from Millipore (Watford, U.K.) and anti-Histone H3 Ser28 and Ki67 antibodies were purchased from Abcam (Cambridge, U.K.) Horseradish-peroxidase-conjugated secondary antibodies were purchased from DakoCytomation (Ely, U.K.) and AlexaFluor(R) 568 and 488 anti-mouse IgG secondary antibodies were purchased from Molecular Probes (Eugene, OR, U.S.A.). Vectashield mounting medium containing DAPI (4',6-diamidino-2-phenylindole) was purchased from Vector Laboratories (Orton Southgate, Peterborough, U.K.). Expression vector pIRES2-EGFP (enhanced green fluorescent protein) was obtained from BD Clontech UK (Basingstoke, U.K.). Quantity One(R) software package was from Bio-Rad (Hemel Hempstead, U.K.). BD Matrigeltrade mark Matrix (growth factor reduced) was supplied by Fahrenheit Laboratories (Milton Keynes, U.K.). All other chemicals and biochemicals were supplied by Sigma.
###end p 20
###begin title 21
HeLa Cell Proliferation Assay
###end title 21
###begin p 22
HeLa cells (5x105) were plated into 6 well dishes and maintained in DMEM supplemented with 10% FCS for 24 hours prior to infection. Cells were infected at an MOI of 50 and cell number was assessed by Coulter Counter at 48 hours post infection. Cells were washed, trypsinised and resuspended in Isoton II solution (Beckton Dickinson, Oxford, U.K.) prior to counting.
###end p 22
###begin title 23
Cardiomyocyte isolation
###end title 23
###begin p 24
###xml 216 220 216 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Vara1">[12]</xref>
###xml 222 226 222 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Bicknell2">[18]</xref>
###xml 601 605 601 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Burton2">[10]</xref>
###xml 607 611 607 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Movassagh1">[13]</xref>
###xml 180 191 <span type="species:ncbi:10116">Wistar rats</span>
###xml 355 359 <span type="species:ncbi:9913">calf</span>
###xml 552 563 <span type="species:ncbi:10116">Wistar rats</span>
Fetal [gestational day 18 (E18)] and neonatal [2- (P2), 3- (P3), 5- (P5), 7- (P7) and 10- (P10) days old] ventricular cardiomyocytes were isolated from 30-70 excised ventricles of Wistar rats as described previously [12], [18]. Cells were maintained in either serum-free (0%) myocyte media (80% DMEM, 20% M199) or myocyte media supplemented with 5% fetal calf serum (FCS). Cardiomyocyte-enriched cultures were at least 95% pure, as determined by anti-tropomyosin staining. Adult ventricular cardiomyocytes were isolated from the excised hearts of male Wistar rats (175-200 g) by Langendorff perfusion [10], [13] and maintained in modified M199 media (M199 supplemented with 2 mM creatine, 2 mM carnitine and 5 mM taurine).
###end p 24
###begin title 25
Quantitative PCR
###end title 25
###begin p 26
###xml 150 176 141 167 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- CTCCCGAACCACTGGTTCC-3&#8242;</named-content>
###xml 202 233 193 224 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- CTTAATAAAGGTGTGGAGAACCCC-3&#8242;</named-content>
###xml 251 286 242 277 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TAMRATGCCTGACCGTCCCCGGAGAFAM- 3&#8242;</named-content>
###xml 303 330 294 321 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GTCCTTTCAGTGGGTCACCAA-3&#8242;</named-content>
###xml 350 380 341 371 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- GTGTGGTCTGAGAGCTGGTATCC-3&#8242;</named-content>
###xml 398 442 389 433 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TAMRATGGGTCGACTACTCCAACAAATACGGCTT-FAM-3&#8242;</named-content>
###xml 459 485 450 476 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GCCTACGCGGTCAAAGTCA-3&#8242;,</named-content>
###xml 505 535 496 526 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- TTATGATCTTCTCGCGCTGATG-3&#8242;,</named-content>
###xml 552 586 543 577 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TAMRACCGCAGAGTCGCGTCGCCAFAM- 3&#8242;</named-content>
###xml 607 635 598 626 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- AAGCAGAATGAGCGAGAATAG-3&#8242;</named-content>
###xml 656 686 647 677 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- CCTTCCACTGTCACAGCAGAAG- 3&#8242;</named-content>
###xml 698 742 689 733 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TAMRACGGCTTTCCCAACACAGACACCAGTACTC-FAM-3&#8242;</named-content>
###xml 127 130 <span type="species:ncbi:10116">Rat</span>
###xml 178 181 <span type="species:ncbi:10116">Rat</span>
###xml 235 238 <span type="species:ncbi:10116">Rat</span>
###xml 331 334 <span type="species:ncbi:10116">Rat</span>
###xml 382 385 <span type="species:ncbi:10116">Rat</span>
###xml 486 489 <span type="species:ncbi:10116">Rat</span>
###xml 536 539 <span type="species:ncbi:10116">Rat</span>
###xml 593 596 <span type="species:ncbi:10116">Rat</span>
###xml 642 645 <span type="species:ncbi:10116">Rat</span>
###xml 688 691 <span type="species:ncbi:10116">Rat</span>
Primers and probes were designed using Primer Expresstrade mark Software (Applied Biosystems, Warrington, UK) as follows: Plk1 Rat Plk1 QPCR-Fwd 1121:5'- CTCCCGAACCACTGGTTCC-3', Rat Plk1 QPCR-Rev 1189: 5'- CTTAATAAAGGTGTGGAGAACCCC-3', Rat Plk1 Probe: 5'-TAMRATGCCTGACCGTCCCCGGAGAFAM- 3'; Plk2 QPCR-Fwd: 5'-GTCCTTTCAGTGGGTCACCAA-3' Rat Plk2 QPCR-Rev: 5'- GTGTGGTCTGAGAGCTGGTATCC-3', Rat Plk2 Probe: 5'-TAMRATGGGTCGACTACTCCAACAAATACGGCTT-FAM-3'; Plk3 QPCR-Fwd: 5'-GCCTACGCGGTCAAAGTCA-3', Rat Plk3 QPCR-Rev: 5'- TTATGATCTTCTCGCGCTGATG-3', Rat Plk3 Probe: 5'-TAMRACCGCAGAGTCGCGTCGCCAFAM- 3'; QPCR Rat Plk4-Fwd: 5'- AAGCAGAATGAGCGAGAATAG-3', QPCR Rat Plk4-Rev: 5'- CCTTCCACTGTCACAGCAGAAG- 3', Rat Plk4: 5'-TAMRACGGCTTTCCCAACACAGACACCAGTACTC-FAM-3'.
###end p 26
###begin title 27
Adenovirus-infection studies
###end title 27
###begin p 28
Recombinant adenoviruses expressing wild-type (WT) or constitutively active Plk1 (T210D) or EGFP alone were generated using the AdEasy System (QBiogene, Carlsbad, USA). For adult cardiomyocyte infection studies, isolated adult myocytes were plated in serum-free modified M199 medium (M199 containing 2 mM creatine, 5 mM taurine and 2 mM carnitine) for 1 hr on Matrigeltrade mark-coated six-well dishes. Adherent adult cardiomyocytes were washed and then infected at a MOI (multiplicity of infection) of 50 plaque forming units of each virus per cell in modified M199 medium. Infected cultures were maintained in modified M199 medium for 24 h before analysis. Neonatal cells were transfected 24 hours after isolation. Cells were washed with PBS and infected in either serum-free M199 media or M199 supplemented with 5% FCS. Cells were incubated for 48 hours prior to analysis.
###end p 28
###begin title 29
Western Blotting
###end title 29
###begin p 30
###xml 87 91 87 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Burton2">[10]</xref>
###xml 93 97 93 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Movassagh1">[13]</xref>
Protein expression levels were determined by SDS-PAGE analysis as previously described [10], [13].
###end p 30
###begin title 31
In vitro kinase assays
###end title 31
###begin p 32
###xml 198 202 194 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Bicknell2">[18]</xref>
###xml 399 400 392 393 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 402 403 395 396 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 909 910 872 873 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 713 718 <span type="species:ncbi:10090">mouse</span>
Cdc2/cyclin B1 immunocomplexes were immunoprecipitated from 250 microg of protein extracted from infected cultures using anti-cyclin B1 antibody and kinase activity measured as described previously [18]. For Plk1 kinase assays, protein lysate was prepared from infected cell cultures in TBSN lysis buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 1 mM EGTA, 25 mM beta-glycerophosphate, 25 mM NaF, 0.5 mM Na3VO4, 10 mM p-nitro phenylphosphate (pNPP), 0.1% Nonidet P-40, 72 microg/ml AEBSF, 10 microg/ml leupeptin, 5 microg/ml aprotinin). Samples were precleared with 30 microl Protein-G Agarose beads at 0.1 g/ml (Sigma) at 4degreesC on a rotating wheel for 1 hour. Plk1 was immunoprecipitated with 1.5 microl monoclonal mouse anti-Plk1 antibody cocktail (Zymed) and pulled down with 30 microl Protein G-Agarose. Immunoprecipitated Plk1 was washed twice in TBSN buffer and twice in TDSN (50 mM Tris pH 7.5, 10 mM MgCl2, 5 mM dithiothreitol (DTT), 2 mM EGTA, 0.5 mM sodium vanadate, 20 mM p-nitrophenyl phosphate) and incubated with 4 microg casein, 10 microCi AT32P and 10 microM ATP in 25 microl TDSN buffer at 30degreesC for 30 minutes. The reaction was terminated by boiling the samples in 1X Laemmli buffer with 0.2 M dithiothreitol (DTT) for 5 minutes. Samples were loaded on a 10% polyacrylamide gel and transferred onto nitrocellulose membrane. Membranes were assessed with a phosphorimager cassette (Molecular Dynamics) for the desired time.
###end p 32
###begin title 33
Immunocytochemistry
###end title 33
###begin p 34
###xml 484 488 <span type="species:ncbi:9925">goat</span>
###xml 687 692 <span type="species:ncbi:10090">mouse</span>
###xml 757 763 <span type="species:ncbi:9986">rabbit</span>
Neonatal cardiomyocytes were cultured in 5% myocyte media on gelatin-coated glass coverslips for 24 h before infection with recombinant adenoviruses. Adult cardiomyocytes were plated on to Matrigeltrade mark-coated chamber slides for 1 hr before infection with recombinant adenoviruses. Cell monolayers were fixed in 1% (v/v) formaldehyde in PBS for 10 min at room temperature (21degreesC), permeabilised with 0.5% (v/v) Triton X-100 in PBS for 15 min and blocked in 10% (v/v) normal goat serum/2% (w/v) BSA in PBS for 30 min. Cardiac myocytes were identified by staining with cardiac myocyte markers: anti-tropomyosin (sarcomeric) monoclonal antibody (clone CH1) was detected with anti-mouse IgG AlexaFluor(R) 568 or anti-troponin I was detected with anti-rabbit IgG AlexaFluor(R) 488 conjugate. These markers were used to distinguish cardiomyocytes from non-myocytes. Images were collected using an Axioskop2 microscope in conjunction with AxioVision software (Zeiss).
###end p 34
###begin title 35
Statistical analysis
###end title 35
###begin p 36
All results are presented as means+/-standard error of the mean (SEM). Data were analyzed by one-way ANOVA followed by the appropriate t-test, with P<0.05 considered to be statistically significant.
###end p 36
###begin title 37
Results
###end title 37
###begin title 38
###xml 48 51 <span type="species:ncbi:10116">rat</span>
Expression and activity of Plk1 declines during rat cardiac myocyte development
###end title 38
###begin p 39
###xml 358 367 358 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006752-g001">Figure 1A</xref>
###xml 414 423 414 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006752-g001">Figure 1B</xref>
###xml 617 628 617 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006752-g001">Figure 1B&#8211;E</xref>
Based upon previous studies showing the downregulation of positive regulators of cell cycle molecules during cardiac myocyte development, we hypothesized that the expression of Plk1 would be downregulated as these cells progressed towards full differentiation. Quantitative PCR analysis revealed a progressive decline in Plk1 mRNA levels during development (Figure 1A) and this was also seen at the protein level (Figure 1B). No Plk1 protein was detected in adult cardiac myocytes. Interestingly, the activity of Plk1 does not change significantly at P10, compared to P3 levels, despite a decline in Plk1 expression (Figure 1B-E). These results suggest that there is a change in the regulation of Plk1 leading to increased activity at P10 compared to levels in P3 cardiac myocytes that is independent of protein synthesis.
###end p 39
###begin title 40
###xml 45 48 <span type="species:ncbi:10116">rat</span>
Plk1 expression and activity declines during rat cardiac myocyte development.
###end title 40
###begin p 41
###xml 55 58 <span type="species:ncbi:10116">rat</span>
Ventricular cardiac myocytes were isolated from Wistar rat hearts at various stages of development (embryonic day 18 [E18], 2, 5 and 10 days postnatal [P2, P5 and P10] and adult [250 g males]) and assessed for Plk1 mRNA (A, normalised to GAPDH) and protein (B, normalised to GAPDH) expression and activity (C). D) representative western blot of Plk1 expression. E) Representative kinase assay and corresponding protein expression (GAPDH was used as a loading control). Data is from three separate experiments, * p<0.05.
###end p 41
###begin title 42
###xml 54 57 <span type="species:ncbi:10116">rat</span>
mRNA and protein levels of Plk2, Plk3 and Plk4 during rat cardiac myocyte development
###end title 42
###begin p 43
###xml 265 274 265 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006752-g002">Figure 2A</xref>
###xml 399 408 399 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006752-g002">Figure 2B</xref>
###xml 537 546 525 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006752-g002">Figure 2C</xref>
###xml 623 638 611 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006752-g003">Figures 3A to F</xref>
###xml 706 715 694 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006752-g001">Figure 1B</xref>
###xml 1186 1201 1162 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006752-g003">Figure 3E and F</xref>
Quantitative PCR revealed differential patterns of regulation for Plk2, Plk3 and Plk4 mRNA during the postnatal developmental period; all are significantly downregulated in the adult. Plk2 showed very little change from E18 levels throughout postnatal development (Figure 2A) whereas Plk3 showed a small, but significant, increase in mRNA levels during the early postnatal growth phase (P2 and P5) (Figure 2B). Plk4 showed a small, significant decrease at P2 and is downregulated by approximately90% in the adult compared to E18 levels (Figure 2C). At the protein level, Plk2, Plk3 and Plk4 are all expressed in the adult (Figures 3A to F), unlike Plk1, which is not be detected in adult cardiac myocytes (Figure 1B). Plk2 protein levels showed a considerable degree of variability between samples (n = 5); protein levels do not appear to change significantly during development. Plk3 protein expression also remains unchanged during early postnatal development, but does appear to be downregulated in the adult heart by approximately40% compared to embryonic day 18 (E18). Plk4 protein levels decrease as development proceeds, with a significant downregulation at P2 and in the adult (Figure 3E and F).
###end p 43
###begin title 44
Regulation of Plk2, Plk3 and Plk4 mRNA expression during cardiac myocyte development.
###end title 44
###begin p 45
Ventricular cardiac myocytes were isolated from hearts at various stages of development (embryonic day 18 [E18], 2, 5 and 10 days postnatal [P2, P5 and P10] and adult [250 g males]) and assessed for Plk2, Plk3 and Plk4 mRNA (black bars, A, B and C, respectively). Samples were normalised to GAPDH. Each bar chart represents data from at least 3 separate experiments, * p<0.05.
###end p 45
###begin title 46
Expression of Plk2, Plk3 and Plk4 protein levels are regulated during cardiac myocyte development.
###end title 46
###begin p 47
Ventricular cardiac myocytes were isolated from hearts at various stages of development (embryonic day 18 [E18], 2, 5 and 10 days postnatal [P2, P5 and P10] and adult [250 g males]) and assessed for Plk2, Plk3 and Plk4 protein expression (A, C and E, respectively, black bars). Samples were normalised to GAPDH. Each bar chart represents data from at least 3 separate experiments, * p<0.05. Representative blots are shown for Plk2 (B), Plk3 ((D) and Plk4 (F).
###end p 47
###begin p 48
Based upon the data showed here, Plk1 is the most interesting candidate for re-initiation of cell cycle in adult cardiac myocytes. No protein expression or activity is detectable in the adult heart, whereas Plk2-4 are all expressed, albeit at lower levels, compared to E18.
###end p 48
###begin title 49
Adenoviral expression of active Plk1 in both HeLa cells and cardiac myocytes
###end title 49
###begin p 50
###xml 11 16 11 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 23 27 23 27 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Petronczki1">[48]</xref>
###xml 1016 1031 1014 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006752-g004">Figure 4A and B</xref>
###xml 1305 1313 1301 1309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1449 1458 1445 1454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006752-g004">Figure 4C</xref>
###xml 278 281 <span type="species:ncbi:10116">rat</span>
Petronczki et al (2007)[48] have shown that inhibition of Plk1 in HeLa cells released from a metaphase block results in binucleation. The majority of adult cardiac myocytes are binucleated and do not express Plk1. We hypothesized that reintroduction of Plk1 into isolated adult rat cardiac myocytes might drive the cells through a successful round of nuclear and/or cell division, thereby increasing cell number. Accordingly, we generated adenoviruses carrying Plk1 in conjunction with an internal ribosomal entry site (IRES) and EGFP marker. To confirm the ability of the Plk1 construct to induce cell cycle progression in proliferating cells, HeLa cells were infected with adenovirus containing either EGFP, wild-type or constitutively active (T210D) Plk1 at a multiplicity of infection (MOI) of 50 (50 virus particles per cell). Forty eight hours post infection, we found that over-expression of wild-type (WT) Plk1 increased the number of HeLa cells by 23+/-5.6% (n = 3, p = 0.02), compared to the EGFP control (Figure 4A and B). Constitutively active Plk1 (T210D) also increased HeLa cell numbers by 20+/-1.5% above the EGFP control. This data shows that adenovirus-delivered Plk1 was able to induce cell division in proliferative cells. We then assessed the activity of adenovirus-delivered Plk1 by in vitro kinase assay in non-proliferating P10 cardiac myocytes: Plk1 kinase activity was increased in both WT and T210D Plk1 expressing cells (Figure 4C).
###end p 50
###begin title 51
Effect of adenovirus-delivered Plk1 on HeLa cell number and Plk1 activity.
###end title 51
###begin p 52
Plk1 enhanced cell division in HeLa cells at 48 hours post infection (A and B). The activity of adenovirus-delivered Plk1 was assessed in P10 cardiac myocytes (C).
###end p 52
###begin title 53
Over-expression of catalytically active Plk1 has no effect on cardiac myocyte binucleation
###end title 53
###begin p 54
###xml 757 766 721 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006752-g005">Figure 5A</xref>
###xml 931 950 895 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006752-g005">Figures 5B, C and D</xref>
###xml 1443 1452 1407 1416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006752-g005">Figure 5E</xref>
###xml 198 201 <span type="species:ncbi:10116">rat</span>
We next determined the effect of over expressing catalytically active WT and T210D Plk1 on cardiac myocyte cell binucleation. Ventricular cardiac myocytes were isolated from P3, P7 and adult Wistar rat hearts and subjected to adenovirus infection as above; P7 cardiac myocytes were chosen due to their improved viability following isolation compared to P10 cells (data not shown). The effect of EGFP, WT or constitutively active (T210D) Plk1 expression on cardiac myocyte binucleation was assessed by calculating the number of nuclei per cardiac myocyte. For uninfected postnatal cells, the number of binucleated cells increased from approximately20% at P3 to approximately40% at P7. Adult cardiac myocytes showed extensive (approximately90%) binucleation (Figure 5A). Surprisingly, we found adenovirus-delivered Plk1 did not have a significant effect on the percentage of binucleated cardiac myocytes at any stage of development (Figures 5B, C and D). This was somewhat surprising, especially at P3 where there is still a capacity for cell division. To determine whether there had been an effect on cell number but not on binucleation, we performed cell counts at P3 and found that there was no significant increase in cardiac myocyte cell number when the cells were incubated in either serum free media (n = 3, WT p = 0.378; T210D p = 0.100) or media supplemented with 5% FCS (n = 3, WT p = 0.277, T210D p = 0.892) compared to EGFP control (Figure 5E). Cell counts were performed on permeabilised, fixed samples stained with cardiac specific markers so rule out increases in cell number by contaminating cardiac fibroblast cells.
###end p 54
###begin title 55
Over expression of Plk1 has no effect on adult cardiac myocyte binucleation.
###end title 55
###begin p 56
###xml 206 210 <span type="species:ncbi:9913">calf</span>
Ventricular cardiac myocytes were isolated and infected with EGFP, WT or T210D adenovirus and incubated for 48 hours (P3 and P7) or 24 hours (adult) in serum free media or media supplemented with 5% foetal calf serum (FCS). Cells were fixed and assessed for binucleation. A) Cardiac myocyte binucleation increases with age. Over expression of Plk1 had no effect on binucleation at P3 (B), P7 (C) or adult (D) stages of development. E) Plk1 over expression does not increase cardiac myocyte cell number, as determined by the number of troponin I positive cardiac myocytes per image (cells were counted for three separate images for EGFP, WT and T210D-infected cells from three separate experiments).
###end p 56
###begin title 57
Over-expression of Plk1 does not increase the activity of Cdc2/cyclin B1 in P3 cardiac myocytes
###end title 57
###begin p 58
###xml 225 229 225 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Bicknell2">[18]</xref>
###xml 317 321 317 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-ToyoshimaMorimoto1">[37]</xref>
###xml 323 327 323 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-ToyoshimaMorimoto2">[42]</xref>
###xml 401 405 401 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Watanabe1">[43]</xref>
###xml 407 411 407 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Nakajima1">[45]</xref>
###xml 413 417 413 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Chow1">[61]</xref>
###xml 805 813 805 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006752-g006">Figure 6</xref>
###xml 511 514 <span type="species:ncbi:10116">rat</span>
###xml 888 891 <span type="species:ncbi:10116">rat</span>
Whilst over-expression of Plk1 had no effect on binucleation in adult cardiac myocytes, it was surprising that Plk1 had no effect on P3 cardiac myocytes at all. P3 cardiac myocytes express the mitotic regulator Cdc2/cyclin B1[18] and retain a limited proliferative capacity. Plk1 promotes activation of Cdc2/cyclin B1[37], [42] and inhibits the activity of the Cdc2/cyclin B1 inhibitors, Wee1 and Myt1[43], [45], [61]. Therefore, we evaluated the effect of Plk1 over expression on Cdc2/cyclin B1 activity in P3 rat cardiac myocytes to determine whether this might explain the lack of cell cycle progression. Interestingly, the activity of Plk1 increased in cells infected with both wild-type and constitutively active Plk1 adenovirus, whereas the activity of Cdc2/cyclin B1 in these cells was unaffected (Figure 6). This data shows that the activation of Cdc2/cyclin B in differentiating rat cardiac myocytes cannot be achieved solely by the over expression of Plk1 and highlights the complexity of cell cycle regulation in cardiac myocytes. This work shows that careful consideration is required when choosing which molecules should be selected for these studies. It is clear that the cell cycle must be manipulated in precisely the right way in order to elicit cell cycle progression.
###end p 58
###begin title 59
###xml 90 93 <span type="species:ncbi:10116">rat</span>
Exogenous Plk1 does not increase the activity of endogenous Cdc2/cyclin B1 in isolated P3 rat cardiac myocytes.
###end title 59
###begin p 60
###xml 48 59 <span type="species:ncbi:10116">Wistar rats</span>
Ventricular cardiac myocytes were isolated from Wistar rats 3 days after birth (P3). Adenovirus expressing EGFP, WT or T210D was used to infect cells for 48 hours. Cells were harvested and assessed for Plk1 and Cdc2/cyclin B1 kinase activity. Plk1 activity was assessed by its ability to phosphorylate casein (A, upper panel). Cdc2/cyclin B1 activity was assessed by phosphorylation of histone H3 (A, lower panel). B) Representative western blot of Plk1 over expression in P3 cardiac myocytes infected with EGFP, WT or T210D adenovirus. GAPDH was used to verify equal loading.
###end p 60
###begin title 61
Cardiac myocytes do not express G2/M markers
###end title 61
###begin p 62
###xml 286 290 286 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Poolman2">[14]</xref>
###xml 292 296 292 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Li1">[15]</xref>
###xml 298 302 298 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Li2">[62]</xref>
###xml 304 308 304 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Poolman3">[63]</xref>
###xml 411 419 411 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 419 423 419 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Bicknell2">[18]</xref>
###xml 993 1001 993 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006752-g006">Figure 6</xref>
###xml 981 984 <span type="species:ncbi:10116">rat</span>
The current study aimed to determine whether Plk1 could be a potential therapeutic target for the initiation of cardiac repair in the mammalian heart. This hypothesis was based on previous studies that have shown that a significant population of adult cardiac myocytes is G2/M arrested [14], [15], [62], [63]], and that over expression of the G2/M regulator Cdc2/cyclin B1 is sufficient to increase cell number in vitro[18]. Although the data presented here shows that Plk1 is unable to do this, it does highlight that a more definitive understanding of the arrest in cardiac myocytes is necessary in order to successfully identify potential targets for a gene therapy approach. In order to further characterise the arrest in cardiac myocytes, and a therefore provide a smaller number of potential targets, we decided to more precisely define the point within the G2/M arrest that these cells are arrested in. Four micrometre sections were taken from E18, P3, P10 and adult Wistar rat hearts (Figure 6) and assessed for the expression of Ki67 and phosphorylation of histone H3 at serine 10 (Ser10) and at serine 28 (Ser28).
###end p 62
###begin p 63
###xml 211 215 211 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Scholzen1">[64]</xref>
###xml 319 323 319 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Hendzel1">[65]</xref>
###xml 324 328 324 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Allison1">[67]</xref>
###xml 446 450 446 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Goto1">[68]</xref>
###xml 529 533 529 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Goto1">[68]</xref>
The proliferation marker, Ki67, is present in all phases of the cell cycle, increasing from G1 to maximal intensity at the metaphase-anaphase transition, but is not found in telophase nor in quiescent, G0, cells[64]. Histone H3 becomes phosphorylated on Ser10 during late G2 and is important for chromosome condensation[65]-[67]. Ser28 is also phosphorylated during mitosis, and like Ser10 phosphorylation, contributes to chromosome condensation [68]. However, unlike Ser10, Ser28 is not phosphorylated until the onset of mitosis[68] and therefore serves as a more faithful mitotic marker.
###end p 63
###begin p 64
###xml 99 107 99 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006752-g007">Figure 7</xref>
###xml 466 470 458 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Poolman2">[14]</xref>
###xml 472 476 464 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Li1">[15]</xref>
###xml 1196 1200 1188 1192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Winkles1">[69]</xref>
###xml 877 880 <span type="species:ncbi:10116">rat</span>
The expression of Ki67 and the phosphorylation of histone H3 at Ser10 and Ser28 declined with age (Figure 7). Very few (Ki67, 0.49+/-0.25%; Ser10, 0.35+/-0.27%; Ser28, 0.29+/-0.15%; n = 3, mean+/-SEM) troponin-I-positive adult cardiac myocytes demonstrated any staining or mitotic figures. Previous studies have investigated the isolated nuclei of adult cardiac myocytes using FACS analysis using dual staining for bromodeoxyuridine (BrdU) and propidium iodide (PI) [14], [15]. This type of analysis determines cell cycle stage by assessing the DNA content of each event (cell or nucleus) as it passes through the laser. Any event displaying a double DNA content, such as a post-S phase, mitotic or binucleated cell, will be classified as a G2/M cell. The lack of any Ser10 or Ser28 staining or mitotic structures suggests that the G2/M population originally observed in adult rat cardiac myocytes most likely represents a population of late S-phase/early G2-arrested cells, rather cells in late G2/M. This might explain why Plk1 is unable to induce cell cycle progression while Cdc2/cyclin B1 can; Cdc2/cyclin B1 reaches its peak activity before the G2/M transition while Plk1 peaks at metaphase[69].
###end p 64
###begin title 65
###xml 47 50 <span type="species:ncbi:10116">rat</span>
Loss of cell cycle markers from the developing rat heart correlates with the decline in proliferative capacity of the cardiac myocyte.
###end title 65
###begin p 66
###xml 75 86 <span type="species:ncbi:10116">Wistar rats</span>
Hearts were excised from embryonic (E18), neonatal (P3 and P10), and adult Wistar rats, frozen in embedding media and sections were cut at 4 microm. Left hand panel (A, C and E) show bar chart summaries (n = 3, SEM, * p<0.05) while the right hand panel (B, D and F) show representative sections for each cell cycle marker at each age group. (B) Cardiac myocytes were identified by the cardiac myocyte-specific marker, tropomyosin (red), histone H3 phosphorylated at Ser10 (green), and nuclei were stained with DAPI (blue). (D) Cardiac myocytes were identified by the cardiac myocyte-specific marker, tropomyosin (red), histone H3 phosphorylated at Ser28 (green), and nuclei were stained with DAPI (blue). (F) Cardiac myocytes were stained with the cardiac myocyte specific marker, troponin I, Ki67 staining is red and DNA was stained with DAPI (blue).
###end p 66
###begin title 67
Discussion
###end title 67
###begin p 68
###xml 131 134 <span type="species:ncbi:10116">rat</span>
In this study, we have determined the expression of the mammalian Plk family of serine/threonine protein kinases in the developing rat cardiac myocyte in an effort to better understand why adult cardiac myocytes are unable to proliferate and repair the damaged myocardium, and to potentially identify novel therapeutic targets that could be manipulated to encourage myocardial repair.
###end p 68
###begin p 69
###xml 72 76 72 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Li3">[70]</xref>
###xml 77 81 77 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Li5">[73]</xref>
###xml 161 164 161 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Poolman1">[2]</xref>
###xml 166 170 166 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Li6">[74]</xref>
###xml 277 281 277 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Warnke1">[52]</xref>
###xml 283 287 283 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Ko1">[56]</xref>
###xml 288 292 288 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Habedanck1">[59]</xref>
Developing cardiac myocytes undergo binucleation during neonatal growth,[70]-[73] whilst adult cells undergo a G1/S transition during the process of hypertrophy.[2], [74]. Both Plk2 and Plk4 are required for S-phase progression and the associated centriole duplication process [52], [56]-[59] and this most likely explains the presence of these two proteins in the adult cardiac myocyte.
###end p 69
###begin p 70
###xml 123 127 123 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Donohue1">[75]</xref>
###xml 197 201 197 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Bahassiel1">[76]</xref>
###xml 203 207 203 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Bahassiel2">[77]</xref>
###xml 286 287 282 283 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 288 289 284 285 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 290 294 286 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Xie1">[54]</xref>
###xml 296 300 292 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Xie2">[78]</xref>
###xml 387 390 <span type="species:ncbi:10116">rat</span>
Plk3 was originally identified as an immediate-early response gene that was upregulated in NIH3T3 cells in response to FGF.[75] It has been reported that Plk3 has a role in G2 checkpoint signaling [76], [77] and is activated following treatment of cells with 100 microM doxorubicin or H2O2.[54], [78] We show here that at the protein level, the expression of Plk3 does not change during rat cardiac myocyte development, with levels persisting to the adult stage. Adult cardiac myocytes are thought to be blocked in G2/M and it is possible that Plk3 could contribute to the arrested state of these cells.
###end p 70
###begin p 71
###xml 246 249 246 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Brooks1">[8]</xref>
###xml 251 255 251 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Brooks2">[11]</xref>
###xml 257 261 257 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Vara1">[12]</xref>
###xml 263 267 263 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Bicknell2">[18]</xref>
###xml 269 273 269 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-TamamoriAdachi2">[21]</xref>
###xml 275 279 275 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Busk1">[23]</xref>
###xml 280 284 280 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Pasumarthi1">[25]</xref>
###xml 319 324 319 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 324 328 324 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Georgescu1">[60]</xref>
###xml 1237 1241 1237 1241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Kaldis1">[79]</xref>
###xml 1386 1390 1386 1390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Desai1">[80]</xref>
###xml 1980 1984 1980 1984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Watanabe1">[43]</xref>
###xml 398 401 <span type="species:ncbi:10116">rat</span>
The decline in Plk1 mRNA and protein levels and activity observed during cardiac myocyte development is consistent with previous studies from our laboratory, and others, examining the expression of other such positive regulators of the cell cycle[8], [11], [12], [18], [21], [23]-[25] and extends the work by Georgescu et al[60]. To investigate the role of Plk1 in nuclear and cellular division in rat cardiac myocytes, we over expressed wild type and constitutively active Plk1 in adult myocytes for 48 hours in the absence or presence of serum to determine whether Plk1 activity could induce cell division. Neither the wild type nor the constitutively active mutant induced any changes in cell cycle progression, in terms of the percentage of binucleated cells, or cell number. Surprisingly, we also found that catalytically active Plk1 was unable to increase the activity of endogenous Cdc2/cyclin B1 in P3 cardiac myocytes, suggesting that Plk1 is unable to complete with the other factors that regulate activity of the Cdc2/cyclin B1 complex. As well as dephosphorylation of Cdc2 at Thr14 and Tyr15 by Cdc25C, phosphorylation of Thr161 in the catalytic T-loop by Cdk activating kinase (CAK) is essential for Cdc2/cyclin B1 activity.[79] It is likely that some of these other factors limit the activation of endogenous Cdc2/cyclin B1; for example, CAK phosphorylates Cdc2 at Thr161 [80] and this modification is required for full activation of the Cdc2/cyclin B1 complex. If Plk1 can only enhance the activity of Cdc2/cyclin B1 that already is phosphorylated at Thr161, the amount of active Plk1 present would be irrelevant if CAK is the rate-limiting factor in Cdc2/cyclin B1 activation. In addition to this, whilst Plk1 has been reported to inhibit the Cdk inhibitor, Wee1, it has been shown that an initial Cdk-mediated phosphorylation of Wee1 at Ser121 is necessary to produce a Plk1 docking site, and that this phosphorylation event is required for increased Plk1 binding[43]. If the Cdk activity in P3 cardiac myocytes is not sufficient to prime Wee1 for Plk1 binding, over expression of Plk1 alone will not be sufficient for Wee1 inhibition and, therefore, an increase in Cdc2/cyclin B1 activity.
###end p 71
###begin p 72
###xml 140 144 140 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Ferrari1">[81]</xref>
###xml 784 788 784 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Poolman2">[14]</xref>
###xml 790 794 790 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Li1">[15]</xref>
###xml 1388 1392 1388 1392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Li1">[15]</xref>
###xml 1711 1715 1711 1715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Meckert1">[82]</xref>
###xml 1805 1809 1805 1809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Meckert1">[82]</xref>
###xml 2066 2070 2066 2070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006752-Li1">[15]</xref>
###xml 768 771 <span type="species:ncbi:10116">rat</span>
###xml 1212 1215 <span type="species:ncbi:10116">rat</span>
Cdc2/cyclin B1 is involved in some of the early stages of mitosis, such as the breakdown of the nuclear envelope and chromosome condensation[81]. Because ectopic Cdc2/cyclin B1 can elicit an increase in the number of adult cardiac myocytes, whilst Plk1 can not, it is possible that in the heart these cells are in an early/mid-G2, rather than in late-G2/M arrest. As such, the introduction of Plk1 into adult myocytes could be too far downstream of this arrest, and therefore unable to bypass the other events that are necessary to occur before mitosis can take place. Based upon the observations reported here, we sought to characterize the G2/M arrest in more detail. Previous reports have suggested that a G2/M arrested population of cardiac myocytes exists in the rat adult heart.[14], [15] To examine this further, we prepared heart sections and assessed them for any evidence of mitotic arrest by the phosphorylation of histone H3 on serine 10 or serine 28. Cells staining positive for cardiac myocyte markers and phosphorylation of either serine residue declined with age, with virtually no adult cardiac myocytes staining positive. The expression of the cell cycle marker, Ki67, was also assessed during rat heart development and was shown to be absent from the adult heart. This data suggests that adult cardiac myocytes are not in a state of 'G2/M' arrest as previously reported[15], but that the arrest could be earlier, such as late S/G2. This raises questions about the involvement of mechanisms of endoreduplication, rather than mitosis, being responsible for cell cycle arrest in the adult cardiac myocyte. Cardiac myocytes are known to increase in terms of ploidy following myocardial infarction[82]. It is possible that the increase in ploidy seen in the myocardium surrounding an infarct[82] is an attempt at cell division that is inhibited by the absence of Cdk or Plk1 activity at G2, leading to rounds of DNA synthesis in the absence of cell division. This may partially explain the presence of the previously reported population of G2/M nuclei;[15] these nuclei may in fact be the product of replication origin re-licensing and endoreduplication rather than an aborted mitosis.
###end p 72
###begin p 73
It is vital that this arrest is characterised in more detail; identifying the precise site of the arrest is important if we are to successfully find new targets for re-initiating cardiac myocyte division post-infarct or during heart failure.
###end p 73
###begin title 74
References
###end title 74
###begin article-title 75
###xml 52 58 <span type="species:ncbi:10090">murine</span>
Cardiomyocyte DNA synthesis and binucleation during murine development.
###end article-title 75
###begin article-title 76
Expressions and activities of cell cycle regulatory molecules during the transition from myocyte hyperplasia to hypertrophy.
###end article-title 76
###begin article-title 77
An intrinsic timer that controls cell-cycle withdrawal in cultured cardiac myocytes.
###end article-title 77
###begin article-title 78
###xml 34 39 <span type="species:ncbi:9606">human</span>
###xml 88 95 <span type="species:ncbi:9606">infants</span>
Cell proliferation in the growing human heart: MIB-1 immunostaining in preterm and term infants at autopsy.
###end article-title 78
###begin article-title 79
Left ventricular remodeling after myocardial infarction: pathophysiology and therapy.
###end article-title 79
###begin article-title 80
Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence.
###end article-title 80
###begin article-title 81
Controversies in ventricular remodelling.
###end article-title 81
###begin article-title 82
Arresting developments in the cardiac myocyte cell cycle: role of cyclin-dependent kinase inhibitors.
###end article-title 82
###begin article-title 83
Differential and dramatic changes of cyclin-dependent kinase activities in cardiomyocytes during the neonatal period.
###end article-title 83
###begin article-title 84
###xml 48 53 <span type="species:ncbi:9606">human</span>
Cyclin-dependent kinase inhibitor expression in human heart failure. A comparison with fetal development.
###end article-title 84
###begin article-title 85
###xml 80 83 <span type="species:ncbi:10116">rat</span>
Expression and activities of cyclins and cyclin-dependent kinases in developing rat ventricular myocytes.
###end article-title 85
###begin article-title 86
Inhibition of E2F abrogates the development of cardiac myocyte hypertrophy.
###end article-title 86
###begin article-title 87
###xml 59 62 <span type="species:ncbi:10116">rat</span>
Characterisation and regulation of E2F-6 and E2F-6b in the rat heart: a potential target for myocardial regeneration?
###end article-title 87
###begin article-title 88
###xml 116 120 <span type="species:ncbi:10090">mice</span>
Altered expression of cell cycle proteins and prolonged duration of cardiac myocyte hyperplasia in p27KIP1 knockout mice.
###end article-title 88
###begin article-title 89
###xml 98 102 <span type="species:ncbi:10116">rats</span>
Role of G1 phase cyclins and cyclin-dependent kinases during cardiomyocyte hypertrophic growth in rats.
###end article-title 89
###begin article-title 90
Stem Cell Differentiation: Cardiac Repair.
###end article-title 90
###begin article-title 91
Can the cardiomyocyte cell cycle be reprogrammed?
###end article-title 91
###begin article-title 92
###xml 79 82 <span type="species:ncbi:10116">rat</span>
Forced expression of the cyclin B1-CDC2 complex induces proliferation in adult rat cardiomyocytes.
###end article-title 92
###begin article-title 93
Reactivation of the mitosis-promoting factor in postmitotic cardiomyocytes.
###end article-title 93
###begin article-title 94
###xml 58 61 <span type="species:ncbi:10116">rat</span>
Down-regulation of p27Kip1 promotes cell proliferation of rat neonatal cardiomyocytes induced by nuclear expression of cyclin D1 and CDK4. Evidence for impaired Skp2-dependent degradation of p27 in terminal differentiation.
###end article-title 94
###begin article-title 95
Critical role of cyclin D1 nuclear import in cardiomyocyte proliferation.
###end article-title 95
###begin article-title 96
p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes.
###end article-title 96
###begin article-title 97
Cyclin D2 induces proliferation of cardiac myocytes and represses hypertrophy.
###end article-title 97
###begin article-title 98
Cyclin A2 mediates cardiomyocyte mitosis in the postmitotic myocardium.
###end article-title 98
###begin article-title 99
###xml 98 113 <span type="species:ncbi:10090">transgenic mice</span>
Targeted expression of cyclin D2 results in cardiomyocyte DNA synthesis and infarct regression in transgenic mice.
###end article-title 99
###begin article-title 100
Cardiomyocyte cell cycle activation improves cardiac function after myocardial infarction.
###end article-title 100
###begin article-title 101
Polo-like kinases: positive regulators of cell division from start to finish.
###end article-title 101
###begin article-title 102
Polo-like kinases and the orchestration of cell division.
###end article-title 102
###begin article-title 103
Mutation of the polo-box disrupts localization and mitotic functions of the mammalian polo kinase Plk.
###end article-title 103
###begin article-title 104
Functional studies on the role of the C-terminal domain of mammalian polo-like kinase.
###end article-title 104
###begin article-title 105
Phosphorylation: polo kinase joins an elite club.
###end article-title 105
###begin article-title 106
The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain.
###end article-title 106
###begin article-title 107
Purification and molecular cloning of Plx1, a Cdc25-regulatory kinase from Xenopus egg extracts.
###end article-title 107
###begin article-title 108
###xml 35 59 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
A multicopy suppressor gene of the Saccharomyces cerevisiae G1 cell cycle mutant gene dbf4 encodes a protein kinase and is identified as CDC5.
###end article-title 108
###begin article-title 109
###xml 14 39 <span type="species:ncbi:4896">Schizosaccharomyces pombe</span>
The conserved Schizosaccharomyces pombe kinase plo1, required to form a bipolar spindle, the actin ring, and septum, can drive septum formation in G1 and G2 cells.
###end article-title 109
###begin article-title 110
###xml 0 5 <span type="species:ncbi:4932">Yeast</span>
Yeast polo-like kinases: functionally conserved multitask mitotic regulators.
###end article-title 110
###begin article-title 111
Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase.
###end article-title 111
###begin article-title 112
Association of polo-like kinase with alpha-, beta- and gamma-tubulins in a stable complex.
###end article-title 112
###begin article-title 113
Plk phosphorylation regulates the microtubule-stabilizing protein TCTP.
###end article-title 113
###begin article-title 114
Phosphorylation of Nlp by Plk1 negatively regulates its dynein-dynactin-dependent targeting to the centrosome.
###end article-title 114
###begin article-title 115
Polo-like kinase 1 regulates Nlp, a centrosome protein involved in microtubule nucleation.
###end article-title 115
###begin article-title 116
###xml 39 44 <span type="species:ncbi:9606">human</span>
Plk1 promotes nuclear translocation of human Cdc25C during prophase.
###end article-title 116
###begin article-title 117
Cyclin-dependent kinase (CDK) phosphorylation destabilizes somatic Wee1 via multiple pathways.
###end article-title 117
###begin article-title 118
Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells.
###end article-title 118
###begin article-title 119
Identification of a consensus motif for Plk (Polo-like kinase) phosphorylation reveals Myt1 as a Plk1 substrate.
###end article-title 119
###begin article-title 120
Polo-like kinase interacts with proteasomes and regulates their activity.
###end article-title 120
###begin article-title 121
The cyclin-ubiquitin ligase activity of cyclosome/APC is jointly activated by protein kinases Cdk1-cyclin B and Plk.
###end article-title 121
###begin article-title 122
###xml 61 66 <span type="species:ncbi:9606">human</span>
Polo-like kinase 1 triggers the initiation of cytokinesis in human cells by promoting recruitment of the RhoGEF Ect2 to the central spindle.
###end article-title 122
###begin article-title 123
Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a Plk1 substrate.
###end article-title 123
###begin article-title 124
The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.
###end article-title 124
###begin article-title 125
BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
###end article-title 125
###begin article-title 126
Polo-like kinase-2 is required for centriole duplication in mammalian cells.
###end article-title 126
###begin article-title 127
Degradation of a non-cycling mammalian polo-like kinase.
###end article-title 127
###begin article-title 128
Genotoxic stress-induced activation of Plk3 is partly mediated by Chk2.
###end article-title 128
###begin article-title 129
Structure and function of Polo-like kinases.
###end article-title 129
###begin article-title 130
Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis.
###end article-title 130
###begin article-title 131
SAK/PLK4 is required for centriole duplication and flagella development.
###end article-title 131
###begin article-title 132
###xml 37 42 <span type="species:ncbi:9606">human</span>
Plk4-induced centriole biogenesis in human cells.
###end article-title 132
###begin article-title 133
The Polo kinase Plk4 functions in centriole duplication.
###end article-title 133
###begin article-title 134
Downregulation of polo-like kinase correlates with loss of proliferative ability of cardiac myocytes.
###end article-title 134
###begin article-title 135
Differential contribution of inhibitory phosphorylation of CDC2 and CDK2 for unperturbed cell cycle control and DNA integrity checkpoints.
###end article-title 135
###begin article-title 136
Downregulation of cyclin-dependent kinase inhibitors p21 and p27 in pressure-overload hypertrophy.
###end article-title 136
###begin article-title 137
Cell cycle profiles and expressions of p21CIP1 AND P27KIP1 during myocyte development.
###end article-title 137
###begin article-title 138
The Ki-67 protein: from the known and the unknown.
###end article-title 138
###begin article-title 139
Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation.
###end article-title 139
###begin article-title 140
Histone H3 phosphorylation is required for the initiation, but not maintenance, of mammalian chromosome condensation.
###end article-title 140
###begin article-title 141
Loss of p53 has site-specific effects on histone H3 modification, including serine 10 phosphorylation important for maintenance of ploidy.
###end article-title 141
###begin article-title 142
Identification of a novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation.
###end article-title 142
###begin article-title 143
Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues.
###end article-title 143
###begin article-title 144
###xml 45 48 <span type="species:ncbi:10116">rat</span>
Formation of binucleated cardiac myocytes in rat heart: II. Cytoskeletal organisation.
###end article-title 144
###begin article-title 145
###xml 58 61 <span type="species:ncbi:10116">rat</span>
Formation of binucleated myocardial cells in the neonatal rat. An index for growth hypertrophy.
###end article-title 145
###begin article-title 146
###xml 45 48 <span type="species:ncbi:10116">rat</span>
Formation of binucleated cardiac myocytes in rat heart: I. Role of actin-myosin contractile ring.
###end article-title 146
###begin article-title 147
Rapid transition of cardiac myocytes from hyperplasia to hypertrophy during postnatal development.
###end article-title 147
###begin article-title 148
Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system; potential targets for therapy?
###end article-title 148
###begin article-title 149
Identification by targeted differential display of an immediate early gene encoding a putative serine/threonine kinase.
###end article-title 149
###begin article-title 150
Mammalian Polo-like kinase 3 (Plk3) is a multifunctional protein involved in stress response pathways.
###end article-title 150
###begin article-title 151
Priming phosphorylation of Chk2 by polo-like kinase 3 (Plk3) mediates its full activation by ATM and a downstream checkpoint in response to DNA damage.
###end article-title 151
###begin article-title 152
Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway.
###end article-title 152
###begin article-title 153
###xml 32 37 <span type="species:ncbi:9606">human</span>
Analysis of CAK activities from human cells.
###end article-title 153
###begin article-title 154
Effects of phosphorylation by CAK on cyclin binding by CDC2 and CDK2.
###end article-title 154
###begin article-title 155
Protein kinases controlling the onset of mitosis.
###end article-title 155
###begin article-title 156
###xml 73 78 <span type="species:ncbi:9606">human</span>
Endomitosis and polyploidization of myocardial cells in the periphery of human acute myocardial infarction.
###end article-title 156
###begin p 157
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: Fleur Moseley currently works for Innovex Medical Communications, but was working at the University of Reading as a postodoctoral researcher at the time of the study.
###end p 157
###begin p 158
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was funded by a PhD Studentship from Heart Research UK, ref 2463/02/06, awarded to G.B. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 158

